Humoral immunity and antibody-mediated rejection in solid organ transplantation

Seminars in Immunology

Volumn 23, Issue 4, 2011, Pages 224-234

  Montgomery, Robert A ^a   Cozzi, Emanuele ^b   West, Lori J ^c   Warren, Daniel S ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PADOVA   (Italy)

^c UNIVERSITY OF ALBERTA   (Canada)

Author keywords

ABO incompatible; Anti endothelial antibody; Antibody mediated rejection; HLA antibody; Humoral rejection; Positive crossmatch

Indexed keywords

ALLOANTIBODY; BLOOD GROUP ANTIBODY; BORTEZOMIB; CD40 ANTIGEN; CD40 LIGAND; CELL SURFACE IMMUNOGLOBULIN; ECULIZUMAB; HEMAGGLUTININ; HLA ANTIBODY; HLA ANTIGEN; HLA ANTIGEN CLASS 1; HLA ANTIGEN CLASS 2; IMMUNOGLOBULIN; RITUXIMAB;

ACUTE GRAFT REJECTION; ALLOTRANSPLANTATION; ANAMNESIS; ANTIBODY PRODUCTION; ANTIBODY RESPONSE; ANTIGEN BINDING; ANTIGEN RECOGNITION; APOPTOSIS; B LYMPHOCYTE; B LYMPHOCYTE ACTIVATION; BLOOD GROUP ABO INCOMPATIBILITY; CELL EXPANSION; COMPLEMENT ACTIVATION; CYTOKINE PRODUCTION; DRUG MEGADOSE; ENDOTHELIUM CELL; GRAFT REJECTION; HEART FAILURE; HEART TRANSPLANTATION; HELPER CELL; HLA SYSTEM; HUMAN; HUMORAL IMMUNITY; HYPERACUTE GRAFT REJECTION; IMMUNOADSORPTION; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY TRANSPLANTATION; LOW DRUG DOSE; MEMORY CELL; NONHUMAN; ORGAN TRANSPLANTATION; PHENOTYPE; PLASMAPHERESIS; PRE B LYMPHOCYTE; REVIEW; SPLENECTOMY; XENOTRANSPLANTATION;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTIBODY-DEPENDENT CELL CYTOTOXICITY; B-LYMPHOCYTES; COMPLEMENT ACTIVATION; COMPLEMENT C5; GRAFT REJECTION; HLA ANTIGENS; HUMANS; IMMUNITY, HUMORAL; IMMUNOSUPPRESSION; ISOANTIBODIES; ORGAN TRANSPLANTATION;

EID: 80054860913     PISSN: 10445323     EISSN: 10963618     Source Type: Journal    
DOI: 10.1016/j.smim.2011.08.021     Document Type: Review

References (141)

1. Kissmeyer-Nielsen F., Olsen S., Petersen V.P., Fjeldborg O. Hyperacute rejection of kidney allografts, associated with pre-existing humoral antibodies against donor cells. Lancet 1966, 2:662-665.
2. Rydberg L. ABO-incompatibility in solid organ transplantation. Transfus Med 2001, 11:325-342.
3. Williams G.M., Hume D.M., Hudson R.P., Morris P.J., Kano K., Milgrom F. " Hyperacute" renal-homograft rejection in man. N Engl J Med 1968, 279:611-618.
4. Fong S.W., Qaqundah B.Y., Taylor W.F. Developmental patterns of ABO isoagglutinins in normal children correlated with the effects of age, sex, and maternal isoagglutinins. Transfusion 1974, 14:551-559.
5. Springer G.F., Horton R.E. Blood group isoantibody stimulation in man by feeding blood group-active bacteria. J Clin Invest 1969, 48:1280-1291.
6. West L.J., Pollock-Barziv S.M., Dipchand A.I., Lee K.J., Cardella C.J., Benson L.N., et al. ABO-incompatible heart transplantation in infants. N Engl J Med 2001, 344:793-800.
7. West L.J., Karamlou T., Dipchand A.I., Pollock-BarZiv S.M., Coles J.G., McCrindle B.W. Impact on outcomes after listing and transplantation, of a strategy to accept ABO blood group-incompatible donor hearts for neonates and infants. J Thorac Cardiovasc Surg 2006, 131:455-461.
8. Almond C.S., Gauvreau K., Thiagarajan R.R., Piercey G.E., Blume E.D., Smoot L.B., et al. Impact of ABO-incompatible listing on wait-list outcomes among infants listed for heart transplantation in the United States: a propensity analysis. Circulation 2010, 121:1926-1933.
9. Everitt M.D., Donaldson A.E., Casper T.C., Stehlik J., Hawkins J.A., Tani L.Y., et al. Effect of ABO-incompatible listing on infant heart transplant waitlist outcomes: analysis of the United Network for Organ Sharing (UNOS) database. J Heart Lung Transplant 2009, 28:1254-1260.
10. Cooper D.K. Clinical survey of heart transplantation between ABO blood group-incompatible recipients and donors. J Heart Transplant 1990, 9:376-381.
11. Dipchand A.I., Pollock BarZiv S.M., Manlhiot C., West L.J., VanderVliet M., McCrindle B.W. Equivalent outcomes for pediatric heart transplantation recipients: ABO-blood group incompatible versus ABO-compatible. Am J Transplant 2010, 10:389-397.
12. Roche S.L., Burch M., O'Sullivan J., Wallis J., Parry G., Kirk R., et al. Multicenter experience of ABO-incompatible pediatric cardiac transplantation. Am J Transplant 2008, 8:208-215.
13. Fan X., Ang A., Pollock-Barziv S.M., Dipchand A.I., Ruiz P., Wilson G., et al. Donor-specific B-cell tolerance after ABO-incompatible infant heart transplantation. Nat Med 2004, 10:1227-1233.
14. West L.J. B-cell tolerance following ABO-incompatible infant heart transplantation. Transplantation 2006, 81:301-307.
15. Kirk R., Edwards L.B., Kucheryavaya A.Y., Aurora P., Christie J.D., Dobbels F., et al. The registry of the international society for heart and lung transplantation: thirteenth official pediatric heart transplantation report-2010. J Heart Lung Transplant 2010, 29:1119-1128.
16. Terasaki P.I., Mickey M.R., Singal D.P., Mittal K.K., Patel R. Serotyping for homotransplantation. XX. Selection of recipients for cadaver donor transplants. N Engl J Med 1968, 279:1101-1103.
17. Hume D.M., Merrill J.P., Miller B.F., Thorn G.W. Experiences with renal homotransplantation in the human: report of nine cases. J Clin Invest 1955, 34:327-382.
18. Starzl T.E., Marchioro T.L., Holmes J.H., Hermann G., Brittain R.S., Stonington O.H., et al. Renal homografts in patients with major donor-recipient blood group incompatibilities. Surgery 1964, 55:195-200.
19. Montgomery R.A., Gentry S.E., Marks W.H., Warren D.S., Hiller J., Houp J., et al. Domino paired kidney donation: a strategy to make best use of live non-directed donation. Lancet 2006, 368:419-421.
20. Montgomery R.A., Zachary A.A., Ratner L.E., Segev D.L., Hiller J.M., Houp J., et al. Clinical results from transplanting incompatible live kidney donor/recipient pairs using kidney paired donation. JAMA 2005, 294:1655-1663.
21. Segev D.L., Gentry S.E., Warren D.S., Reeb B., Montgomery R.A. Kidney paired donation and optimizing the use of live donor organs. JAMA 2005, 293:1883-1890.
22. Zachary A., Reinsmoen N.L. Quantifying HLA-specific antibodies in patients undergoing desensitization. Curr Opin Organ Transplant 2011, 16:410-415.
23. Pei R., Lee J.H., Shih N.J., Chen M., Terasaki P.I. Single human leukocyte antigen flow cytometry beads for accurate identification of human leukocyte antigen antibody specificities. Transplantation 2003, 75:43-49.
24. Zachary A.A., Delaney N.L., Lucas D.P., Leffell M.S. Characterization of HLA class I specific antibodies by ELISA using solubilized antigen targets: I. Evaluation of the GTI QuikID assay and analysis of antibody patterns. Hum Immunol 2001, 62:228-235.
25. Shirey R.S., Cai W., Montgomery R.A., Chhibber V., Ness P.M., King K.E. Streamlining ABO antibody titrations for monitoring ABO-incompatible kidney transplants. Transfusion 2010, 50:631-634.
26. Novaretti M.C., Jens E., Pagliarini T., Bonifacio S.L., Dorlhiac-Llacer P.E., Chamone D.A. Comparison of conventional tube test technique and gel microcolumn assay for direct antiglobulin test: a large study. J Clin Lab Anal 2004, 18:255-258.
27. Montgomery R.A., Locke J.E., King K.E., Segev D.L., Warren D.S., Kraus E.S., et al. ABO incompatible renal transplantation: a paradigm ready for broad implementation. Transplantation 2009, 87:1246-1255.
28. Warren D.S., Zachary A.A., Sonnenday C.J., King K.E., Cooper M., Ratner L.E., et al. Successful renal transplantation across simultaneous ABO incompatible and positive crossmatch barriers. Am J Transplant 2004, 4:561-568.
29. Irving C., Parry G., Cassidy J., Hasan A., Griselli M., Kirk R. Outcomes following infant listing for cardiac transplantation: the impact of strategies introduced to counteract limited donor availability. Arch Dis Child 2010, 95:883-887.
30. Harmer A.W., Haskard D., Koffman C.G., Welsh K.I. Novel antibodies associated with unexplained loss of renal allografts. Transpl Int 1990, 3:66-69.
31. Jordan S.C., Yap H.K., Sakai R.S., Alfonso P., Fitchman M. Hyperacute allograft rejection mediated by anti-vascular endothelial cell antibodies with a negative monocyte crossmatch. Transplantation 1988, 46:585-587.
32. Sumitran-Karuppan S., Tyden G., Reinholt F., Berg U., Moller E. Hyperacute rejections of two consecutive renal allografts and early loss of the third transplant caused by non-HLA antibodies specific for endothelial cells. Transpl Immunol 1997, 5:321-327.
33. Jackson A.M., Lucas D.P., Melancon J.K., Desai N.M. Clinical relevance and igg subclass determination of non-HLA antibodies identified using endothelial cell precursors isolated from donor blood. Transplantation 2011, 92:54-60.
34. Zwirner N.W., Marcos C.Y., Mirbaha F., Zou Y., Stastny P. Identification of MICA as a new polymorphic alloantigen recognized by antibodies in sera of organ transplant recipients. Hum Immunol 2000, 61:917-924.
35. Dragun D., Muller D.N., Brasen J.H., Fritsche L., Nieminen-Kelha M., Dechend R., et al. Angiotensin II type 1-receptor activating antibodies in renal-allograft rejection. N Engl J Med 2005, 352:558-569.
36. Breinholt J.P., Hawkins J.A., Lambert L.M., Fuller T.C., Profaizer T., Shaddy R.E. A prospective analysis of the immunogenicity of cryopreserved nonvalved allografts used in pediatric heart surgery. Circulation 2000, 102:III179-III182.
37. Meyer S.R., Campbell P.M., Rutledge J.M., Halpin A.M., Hawkins L.E., Lakey J.R., et al. Use of an allograft patch in repair of hypoplastic left heart syndrome may complicate future transplantation. Eur J Cardiothorac Surg 2005, 27:554-560.
38. Schuster M., Kocher A., John R., Hoffman M., Ankersmit J., Lietz K., et al. B-cell activation and allosensitization after left ventricular assist device implantation is due to T-cell activation and CD40 ligand expression. Hum Immunol 2002, 63:211-220.
39. Drakos S.G., Kfoury A.G., Kotter J.R., Reid B.B., Clayson S.E., Selzman C.H., et al. Prior human leukocyte antigen-allosensitization and left ventricular assist device type affect degree of post-implantation human leukocyte antigen-allosensitization. J Heart Lung Transplant 2009, 28:838-842.
40. Berry G.J., Angelini A., Burke M.M., Bruneval P., Fishbein M.C., Hammond E., et al. The ISHLT working formulation for pathologic diagnosis of antibody-mediated rejection in heart transplantation: evolution and current status (2005-2011). J Heart Lung Transplant 2011, 30:601-611.
41. Kobashigawa J., Crespo-Leiro M.G., Ensminger S.M., Reichenspurner H., Angelini A., Berry G., et al. Report from a consensus conference on antibody-mediated rejection in heart transplantation. J Heart Lung Transplant 2011, 30:252-269.
42. Kfoury A.G., Hammond M.E. Controversies in defining cardiac antibody-mediated rejection: need for updated criteria. J Heart Lung Transplant 2010, 29:389-394.
43. Locke J.E., Magro C.M., Singer A.L., Segev D.L., Haas M., Hillel A.T., et al. The use of antibody to complement protein C5 for salvage treatment of severe antibody-mediated rejection. Am J Transplant 2009, 9:231-235.
44. Locke J.E., Zachary A.A., Haas M., Melancon J.K., Warren D.S., Simpkins C.E., et al. The utility of splenectomy as rescue treatment for severe acute antibody mediated rejection. Am J Transplant 2007, 7:842-846.
45. Gloor J.M., Winters J.L., Cornell L.D., Fix L.A., DeGoey S.R., Knauer R.M., et al. Baseline donor-specific antibody levels and outcomes in positive crossmatch kidney transplantation. Am J Transplant 2010, 10:582-589.
46. Gloor J.M., Sethi S., Stegall M.D., Park W.D., Moore S.B., DeGoey S., et al. Transplant glomerulopathy: subclinical incidence and association with alloantibody. Am J Transplant 2007, 7:2124-2132.
47. Kobashigawa J.A., Patel J.K., Kittleson M.M., Kawano M.A., Kiyosaki K.K., Davis S.N., et al. The long-term outcome of treated sensitized patients who undergo heart transplantation. Clin Transplant 2011, 25:E61-E67.
48. Bucin D., Gustafsson R., Ekmehag B., Kornhall B., Algotsson L., Lund U., et al. Desensitization and heart transplantation of a patient with high levels of donor-reactive anti-human leukocyte antigen antibodies. Transplantation 2010, 90:1220-1225.
49. Ross H., Tinckam K., Rao V., West L.J. In praise of ventricular assist devices-mechanical bridge to virtual crossmatch for the sensitized patient. J Heart Lung Transplant 2010, 29:728-730.
50. Montgomery R.A., Zachary A.A., Racusen L.C., Leffell M.S., King K.E., Burdick J., et al. Plasmapheresis and intravenous immune globulin provides effective rescue therapy for refractory humoral rejection and allows kidneys to be successfully transplanted into cross-match-positive recipients. Transplantation 2000, 70:887-895.
51. Kfoury A.G., Hammond M.E., Snow G.L., Drakos S.G., Stehlik J., Fisher P.W., et al. Cardiovascular mortality among heart transplant recipients with asymptomatic antibody-mediated or stable mixed cellular and antibody-mediated rejection. J Heart Lung Transplant 2009, 28:781-784.
52. Lachmann N., Terasaki P.I., Budde K., Liefeldt L., Kahl A., Reinke P., et al. Anti-human leukocyte antigen and donor-specific antibodies detected by luminex posttransplant serve as biomarkers for chronic rejection of renal allografts. Transplantation 2009, 87:1505-1513.
53. Lee P.C., Zhu L., Terasaki P.I., Everly M.J. HLA-specific antibodies developed in the first year posttransplant are predictive of chronic rejection and renal graft loss. Transplantation 2009, 88:568-574.
54. Wu G.W., Kobashigawa J.A., Fishbein M.C., Patel J.K., Kittleson M.M., Reed E.F., et al. Asymptomatic antibody-mediated rejection after heart transplantation predicts poor outcomes. J Heart Lung Transplant 2009, 28:417-422.
55. Loupy A., Cazes A., Guillemain R., Amrein C., Hedjoudje A., Tible M., et al. Very late heart transplant rejection is associated with microvascular injury, complement deposition and progression to cardiac allograft vasculopathy. Am J Transplant 2011, 11:1478-1487.
56. Nath D.S., Tiriveedhi V., Basha H.I., Phelan D., Moazami N., Ewald G.A., et al. A role for antibodies to human leukocyte antigens, collagen-V, and K-alpha1-tubulin in antibody-mediated rejection and cardiac allograft vasculopathy. Transplantation 2011, 91:1036-1043.
57. Issa N., Cosio F.G., Gloor J.M., Sethi S., Dean P.G., Moore S.B., et al. Transplant glomerulopathy: risk and prognosis related to anti-human leukocyte antigen class II antibody levels. Transplantation 2008, 86:681-685.
58. Kraus E.S., Parekh R.S., Oberai P., Lepley D., Segev D.L., Bagnasco S., et al. Subclinical rejection in stable positive crossmatch kidney transplant patients: incidence and correlations. Am J Transplant 2009, 9:1826-1834.
59. Urschel S., Campbell P.M., Meyer S.R., Larsen I.M., Nuebel J., Birnbaum J., et al. Absence of donor-specific anti-HLA antibodies after ABO-incompatible heart transplantation in infancy: altered immunity or age?. Am J Transplant 2010, 10:149-156.
60. Breimer M.E., Rydberg L., Jackson A.M., Lucas D.P., Zachary A.A., Melancon J.K., et al. Multicenter evaluation of a novel endothelial cell crossmatch test in kidney transplantation. Transplantation 2009, 87:549-556.
61. Haas M., Rahman M.H., Racusen L.C., Kraus E.S., Bagnasco S.M., Segev D.L., et al. C4d and C3d staining in biopsies of ABO- and HLA-incompatible renal allografts: correlation with histologic findings. Am J Transplant 2006, 6:1829-1840.
62. Sonnenday C.J., Warren D.S., Cooper M., Samaniego M., Haas M., King K.E., et al. Plasmapheresis, CMV hyperimmune globulin, and anti-CD20 allow ABO-incompatible renal transplantation without splenectomy. Am J Transplant 2004, 4:1315-1322.
63. Chopek M.W., Simmons R.L., Platt J.L. ABO-incompatible kidney transplantation: initial immunopathologic evaluation. Transplant Proc 1987, 19:4553-4557.
64. Bannett A.D., McAlack R.F., Morris M., Chopek M.W., Platt J.L. ABO incompatible renal transplantation: a qualitative analysis of native endothelial tissue ABO antigens after transplantation. Transplant Proc 1989, 21:783-785.
65. Tobian A.A., Shirey R.S., Montgomery R.A., Ness P.M., King K.E. The critical role of plasmapheresis in ABO-incompatible renal transplantation. Transfusion 2008, 48:2453-2460.
66. Tobian A.A., Shirey R.S., Montgomery R.A., Tisch D.J., Ness P.M., King K.E. Therapeutic plasma exchange reduces ABO titers to permit ABO-incompatible renal transplantation. Transfusion 2009, 49:1248-1254.
67. Montgomery R.A., Lonze B.E., King K.E., Kraus E.S., Kucirka L.M., Locke J.E., et al. Desensitization in HLA-incompatible kidney recipients and survival. N Engl J Med 2011, 365:318-326.
68. Genberg H., Kumlien G., Wennberg L., Berg U., Tyden G. ABO-incompatible kidney transplantation using antigen-specific immunoadsorption and rituximab: a 3-year follow-up. Transplantation 2008, 85:1745-1754.
69. Montgomery R.A., Locke J.E. ABO-incompatible transplantation: less may be more. Transplantation 2007, 84:S8-S9.
70. Takahashi K., Saito K., Takahara S., Okuyama A., Tanabe K., Toma H., et al. Excellent long-term outcome of ABO-incompatible living donor kidney transplantation in Japan. Am J Transplant 2004, 4:1089-1096.
71. Eckman P.M. Immunosuppression in the sensitized heart transplant recipient. Curr Opin Organ Transplant 2010, 15:650-656.
72. Jordan S.C., Vo A., Bunnapradist S., Toyoda M., Peng A., Puliyanda D., et al. Intravenous immune globulin treatment inhibits crossmatch positivity and allows for successful transplantation of incompatible organs in living-donor and cadaver recipients. Transplantation 2003, 76:631-636.
73. Glotz D., Antoine C., Julia P., Suberbielle-Boissel C., Boudjeltia S., Fraoui R., et al. Desensitization and subsequent kidney transplantation of patients using intravenous immunoglobulins (IVIg). Am J Transplant 2002, 2:758-760.
74. Jordan S.C., Tyan D., Czer L., Toyoda M. Immunomodulatory actions of intravenous immunoglobulin (IVIG): potential applications in solid organ transplant recipients. Pediatr Transplant 1998, 2:92-105.
75. Yu Z., Lennon V.A. Mechanism of intravenous immune globulin therapy in antibody-mediated autoimmune diseases. N Engl J Med 1999, 340:227-228.
76. Vo A.A., Cam V., Toyoda M., Puliyanda D.P., Lukovsky M., Bunnapradist S., et al. Safety and adverse events profiles of intravenous gammaglobulin products used for immunomodulation: a single-center experience. Clin J Am Soc Nephrol 2006, 1:844-852.
77. Jordan S.C., Tyan D., Stablein D., McIntosh M., Rose S., Vo A., et al. Evaluation of intravenous immunoglobulin as an agent to lower allosensitization and improve transplantation in highly sensitized adult patients with end-stage renal disease: report of the NIH IG02 trial. J Am Soc Nephrol 2004, 15:3256-3262.
78. Stegall M.D., Gloor J., Winters J.L., Moore S.B., Degoey S. A comparison of plasmapheresis versus high-dose IVIG desensitization in renal allograft recipients with high levels of donor specific alloantibody. Am J Transplant 2006, 6:346-351.
79. Vo A.A., Lukovsky M., Toyoda M., Wang J., Reinsmoen N.L., Lai C.H., et al. Rituximab and intravenous immune globulin for desensitization during renal transplantation. N Engl J Med 2008, 359:242-251.
80. Reff M.E., Carner K., Chambers K.S., Chinn P.C., Leonard J.E., Raab R., et al. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood 1994, 83:435-445.
81. Genberg H., Hansson A., Wernerson A., Wennberg L., Tyden G. Pharmacodynamics of rituximab in kidney transplantation. Transplantation 2007, 84:S33-S36.
82. Alexandre G.P., Squifflet J.P., De Bruyere M., Latinne D., Moriau M., Ikabu N., et al. Splenectomy as a prerequisite for successful human ABO-incompatible renal-transplantation. Transplant Proc 1985, 17:138-143.
83. Ishida H., Koyama I., Sawada T., Utsumi K., Murakami T., Sannomiya A., et al. Anti-AB titer changes in patients with ABO incompatibility after living related kidney transplantations: survey of 101 cases to determine whether splenectomies are necessary for successful transplantation. Transplantation 2000, 70:681-685.
84. Tyden G., Kumlien G., Fehrman I. Successful ABO-incompatible kidney transplantations without splenectomy using antigen-specific immunoadsorption and rituximab. Transplantation 2003, 76:730-731.
85. Segev D.L., Simpkins C.E., Warren D.S., King K.E., Shirey R.S., Maley W.R., et al. ABO incompatible high-titer renal transplantation without splenectomy or anti-CD20 treatment. Am J Transplant 2005, 5:2570-2575.
86. Locke J.E., Zachary A.A., Mohammed B.S., Warren D.S., Montgomery R.A. Rescue splenectomy for severe acute antibody-mediated rejection. Clin Transpl 2006, 518-520.
87. Fairfax K.A., Kallies A., Nutt S.L., Tarlinton D.M. Plasma cell development: from B-cell subsets to long-term survival niches. Semin Immunol 2008, 20:49-58.
88. Alexander J.W., First M.R., Majeski J.A., Munda R., Fidler J.P., Morris M.J., et al. The late adverse effect of splenectomy on patient survival following cadaveric renal transplantation. Transplantation 1984, 37:467-470.
89. Malangoni M.A., Dillon L.D., Klamer T.W., Condon R.E. Factors influencing the risk of early and late serious infection in adults after splenectomy for trauma. Surgery 1984, 96:775-783.
90. Woodle E.S., Alloway R.R., Girnita A. Proteasome inhibitor treatment of antibody-mediated allograft rejection. Curr Opin Organ Transplant 2011, 16:434-438.
91. Frischmeyer-Guerrerio P.A., Montgomery R.A., Warren D.S., Cooke S.K., Lutz J., Sonnenday C.J., et al. Perturbation of thymocyte development in nonsense-mediated decay (NMD)-deficient mice. Proc Natl Acad Sci USA 2011, 108:10638-10643.
92. Everly M.J., Everly J.J., Susskind B., Brailey P., Arend L.J., Alloway R.R., et al. Bortezomib provides effective therapy for antibody- and cell-mediated acute rejection. Transplantation 2008, 86:1754-1761.
93. Diwan T.S., Raghavaiah S., Burns J.M., Kremers W.K., Gloor J.M., Stegall M.D. The impact of proteasome inhibition on alloantibody-producing plasma cells in vivo. Transplantation 2011, 91:536-541.
94. Perry D.K., Burns J.M., Pollinger H.S., Amiot B.P., Gloor J.M., Gores G.J., et al. Proteasome inhibition causes apoptosis of normal human plasma cells preventing alloantibody production. Am J Transplant 2009, 9:201-209.
95. Walsh R.C., Everly J.J., Brailey P., Rike A.H., Arend L.J., Mogilishetty G., et al. Proteasome inhibitor-based primary therapy for antibody-mediated renal allograft rejection. Transplantation 2010, 89:277-284.
96. Hillmen P., Young N.S., Schubert J., Brodsky R.A., Socie G., Muus P., et al. The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria. N Engl J Med 2006, 355:1233-1243.
97. Cooper N.R. The classical complement pathway: activation and regulation of the first complement component. Adv Immunol 1985, 37:151-216.
98. Perkins S.J., Nealis A.S. The quaternary structure in solution of human complement subcomponent C1r2C1s2. Biochem J 1989, 263:463-469.
99. Lonze B.E., Dagher N.N., Simpkins C.E., Locke J.E., Singer A.L., Segev D.L., et al. Eculizumab, bortezomib and kidney paired donation facilitate transplantation of a highly sensitized patient without vascular access. Am J Transplant 2010, 10:2154-2160.
100. Lonze B.E., Singer A.L., Montgomery R.A. Eculizumab and renal transplantation in a patient with CAPS. N Engl J Med 2010, 362:1744-1745.
101. Lapeyraque A.L., Malina M., Fremeaux-Bacchi V., Boppel T., Kirschfink M., Oualha M., et al. Eculizumab in severe Shiga-toxin-associated HUS. N Engl J Med 2011, 364:2561-2563.
102. Platt J.L., Lin S.S., McGregor C.G. Acute vascular rejection. Xenotransplantation 1998, 5:169-175.
103. Bach F.H., Winkler H., Ferran C., Hancock W.W., Robson S.C. Delayed xenograft rejection. Immunol Today 1996, 17:379-384.
104. Calne R.Y. Organ transplantation between widely disparate species. Transplant Proc 1970, 2:550-556.
105. Platt J.L., Fischel R.J., Matas A.J., Reif S.A., Bolman R.M., Bach F.H. Immunopathology of hyperacute xenograft rejection in a swine-to-primate model. Transplantation 1991, 52:214-220.
106. Dalmasso A.P., Platt J.L., Bach F.H. Reaction of complement with endothelial cells in a model of xenotransplantation. Clin Exp Immunol 1991, 86(Suppl. 1):31-35.
107. Magee J.C., Collins B.H., Harland R.C., Lindman B.J., Bollinger R.R., Frank M.M., et al. Immunoglobulin prevents complement-mediated hyperacute rejection in swine-to-primate xenotransplantation. J Clin Invest 1995, 96:2404-2412.
108. Platt J.L., Lindman B.J., Geller R.L., Noreen H.J., Swanson J.L., Dalmasso A.P., et al. The role of natural antibodies in the activation of xenogenic endothelial cells. Transplantation 1991, 52:1037-1043.
109. Vanhove B., Bach F.H. Human xenoreactive natural antibodies-avidity and targets on porcine endothelial cells. Transplantation 1993, 56:1251-1253.
110. Good A.H., Cooper D.K., Malcolm A.J., Ippolito R.M., Koren E., Neethling F.A., et al. Identification of carbohydrate structures that bind human antiporcine antibodies: implications for discordant xenografting in humans. Transplant Proc 1992, 24:559-562.
111. Parker W., Bruno D., Holzknecht Z.E., Platt J.L. Characterization and affinity isolation of xenoreactive human natural antibodies. J Immunol 1994, 153:3791-3803.
112. Sandrin M.S., Vaughan H.A., Dabkowski P.L., McKenzie I.F. Anti-pig IgM antibodies in human serum react predominantly with Gal(alpha 1-3)Gal epitopes. Proc Natl Acad Sci USA 1993, 90:11391-11395.
113. Galili U. Interaction of the natural anti-Gal antibody with alpha-galactosyl epitopes: a major obstacle for xenotransplantation in humans. Immunol Today 1993, 14:480-482.
114. Galili U., Shohet S.B., Kobrin E., Stults C.L., Macher B.A. Man, apes, and old world monkeys differ from other mammals in the expression of alpha-galactosyl epitopes on nucleated cells. J Biol Chem 1988, 263:17755-17762.
115. Ezzelarab M., Ayares D., Cooper D.K. Carbohydrates in xenotransplantation. Immunol Cell Biol 2005, 83:396-404.
116. Lee W., Gaca J.G., Edwards L.A., Braedehoeft S.J., Parker W., Davis R.D. Binding of polyreactive antibodies to self versus foreign antigens. Immunobiology 2002, 205:95-107.
117. Logtenberg T. Properties of polyreactive natural antibodies to self and foreign antigens. J Clin Immunol 1990, 10:137-140.
118. Gaca J.G., Lee W., Aksoy O., Braedehoeft S.J., Gonzalez-Stawinski G.V., Parker W., et al. Evidence for polyreactive xenoreactive antibodies in the repertoire of human anti-swine antibodies: the 'next' humoral barrier to xenotransplantation?. Transpl Immunol 2001, 9:19-27.
119. Turman M.A., Casali P., Notkins A.L., Bach F.H., Platt J.L. Polyreactivity and antigen specificity of human xenoreactive monoclonal and serum natural antibodies. Transplantation 1991, 52:710-717.
120. Satapathy A.K., Ravindran B. Naturally occurring alpha-galactosyl antibodies in human sera display polyreactivity. Immunol Lett 1999, 69:347-351.
121. Parker W. Polyreactive antibodies and their association with xenotransplantation. Xenotransplantation 2003, 10:542-544.
122. McMahon M.J., O'Kennedy R. Polyreactivity as an acquired artefact, rather than a physiologic property, of antibodies: evidence that monoreactive antibodies may gain the ability to bind to multiple antigens after exposure to low pH. J Immunol Methods 2000, 241:1-10.
123. Cozzi E., White D.J. The generation of transgenic pigs as potential organ donors for humans. Nat Med 1995, 1:964-966.
124. Diamond L.E., McCurry K.R., Martin M.J., McClellan S.B., Oldham E.R., Platt J.L., et al. Characterization of transgenic pigs expressing functionally active human CD59 on cardiac endothelium. Transplantation 1996, 61:1241-1249.
125. McCurry K.R., Kooyman D.L., Alvarado C.G., Cotterell A.H., Martin M.J., Logan J.S., et al. Human complement regulatory proteins protect swine-to-primate cardiac xenografts from humoral injury. Nat Med 1995, 1:423-427.
126. Dai Y., Vaught T.D., Boone J., Chen S.H., Phelps C.J., Ball S., et al. Targeted disruption of the alpha1,3-galactosyltransferase gene in cloned pigs. Nat Biotechnol 2002, 20:251-255.
127. Adams D.H., Kadner A., Chen R.H., Farivar R.S. Human membrane cofactor protein (MCP, CD 46) protects transgenic pig hearts from hyperacute rejection in primates. Xenotransplantation 2001, 8:36-40.
128. Cozzi E., Bhatti F., Schmoeckel M., Chavez G., Smith K.G., Zaidi A., et al. Long-term survival of nonhuman primates receiving life-supporting transgenic porcine kidney xenografts. Transplantation 2000, 70:15-21.
129. Kuwaki K., Tseng Y.L., Dor F.J., Shimizu A., Houser S.L., Sanderson T.M., et al. Heart transplantation in baboons using alpha1,3-galactosyltransferase gene-knockout pigs as donors: initial experience. Nat Med 2005, 11:29-31.
130. Schuurman H.J., Pino-Chavez G., Phillips M.J., Thomas L., White D.J., Cozzi E. Incidence of hyperacute rejection in pig-to-primate transplantation using organs from hDAF-transgenic donors. Transplantation 2002, 73:1146-1151.
131. Schuurman H.J., Cheng J., Lam T. Pathology of xenograft rejection: a commentary. Xenotransplantation 2003, 10:293-299.
132. Loss M., Vangerow B., Schmidtko J., Kunz R., Jalali A., Arends H., et al. Acute vascular rejection is associated with systemic complement activation in a pig-to-primate kidney xenograft model. Xenotransplantation 2000, 7:186-196.
133. Zaidi A., Schmoeckel M., Bhatti F., Waterworth P., Tolan M., Cozzi E., et al. Life-supporting pig-to-primate renal xenotransplantation using genetically modified donors. Transplantation 1998, 65:1584-1590.
134. Lin S.S., Weidner B.C., Byrne G.W., Diamond L.E., Lawson J.H., Hoopes C.W., et al. The role of antibodies in acute vascular rejection of pig-to-baboon cardiac transplants. J Clin Invest 1998, 101:1745-1756.
135. Shimizu A., Yamada K., Yamamoto S., Lavelle J.M., Barth R.N., Robson S.C., et al. Thrombotic microangiopathic glomerulopathy in human decay accelerating factor-transgenic swine-to-baboon kidney xenografts. J Am Soc Nephrol 2005, 16:2732-2745.
136. Tseng Y.L., Kuwaki K., Dor F.J., Shimizu A., Houser S., Hisashi Y., et al. alpha1,3-Galactosyltransferase gene-knockout pig heart transplantation in baboons with survival approaching 6 months. Transplantation 2005, 80:1493-1500.
137. Byrne G.W., Stalboerger P.G., Davila E., Heppelmann C.J., Gazi M.H., McGregor H.C., et al. Proteomic identification of non-Gal antibody targets after pig-to-primate cardiac xenotransplantation. Xenotransplantation 2008, 15:268-276.
138. Byrne G.W., Stalboerger P.G., Du Z., Davis T.R., McGregor C.G. Identification of new carbohydrate and membrane protein antigens in cardiac xenotransplantation. Transplantation 2011, 91:287-292.
139. Diswall M., Angstrom J., Karlsson H., Phelps C.J., Ayares D., Teneberg S., et al. Structural characterization of alpha1,3-galactosyltransferase knockout pig heart and kidney glycolipids and their reactivity with human and baboon antibodies. Xenotransplantation 2010, 17:48-60.
140. Chen G., Qian H., Starzl T., Sun H., Garcia B., Wang X., et al. Acute rejection is associated with antibodies to non-Gal antigens in baboons using Gal-knockout pig kidneys. Nat Med 2005, 11:1295-1298.
141. Buhler L., Xu Y., Li W., Zhu A., Cooper D.K. An investigation of the specificity of induced anti-pig antibodies in baboons. Xenotransplantation 2003, 10:88-93.